Abstract: Prostate cancer is the most common malignant tumor that threatens the health of middle-aged and elderly men,and the second leading cause of cancer death,only lower than lung cancer.Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed by prostate cancer cells,and it has become an important target for early diagnosis,staging and treatment of prostate cancer.Based on it,radionuclide-labeled PSMA is promising to serve as a potent biomarker for positron emission tomography (PET) imaging.Besides,it plays a unique and important role in the diagnosis and treatment of prostate cancer.This article summarizes the clinical value of PSMA-PET in the diagnosis and treatment of prostate cancer,and aims to provide evidences for clinical diagnosis and treatment.